[go: up one dir, main page]

DK2977053T3 - Sammensætninger og fremgangsmåder til behandling af cøliaki - Google Patents

Sammensætninger og fremgangsmåder til behandling af cøliaki Download PDF

Info

Publication number
DK2977053T3
DK2977053T3 DK15168279.6T DK15168279T DK2977053T3 DK 2977053 T3 DK2977053 T3 DK 2977053T3 DK 15168279 T DK15168279 T DK 15168279T DK 2977053 T3 DK2977053 T3 DK 2977053T3
Authority
DK
Denmark
Prior art keywords
gin
seq
peptide
pro
peptides
Prior art date
Application number
DK15168279.6T
Other languages
English (en)
Inventor
Robert Paul Anderson
Jessica Anne Stewart
James Anthony Dromey
Jason Allan Tye-Din
Original Assignee
Immusant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc filed Critical Immusant Inc
Application granted granted Critical
Publication of DK2977053T3 publication Critical patent/DK2977053T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)

Claims (16)

1. Sammensætning, der omfatter: i) et første peptid, der omfatter aminosyresekvensen PFPQPELPY (SEQ ID NO: 3) eller aminosyresekvensen PQPELPYPQ (SEQ ID NO: 4), ii) et andet peptid, der omfatter aminosyresekvensen PFPQPEQPF (SEQ ID NO: 10) eller aminosyresekvensen PQPEQPFPW (SEQ ID NO: 15) og iii) et tredje peptid, der omfatter aminosyresekvensen PIPEQPQPY (SEQ ID NO: 17) eller aminosyresekvensen EQPIPEQPQ (SEQ ID NO: 18) eller aminosyresekvensen QQPIPEQPQ (SEQ ID NO: 19).
2. Sammensætning ifølge krav 1, hvor (a) det andet peptid omfatter aminosyresekvensen PQQPFPQPEQPFPWQP (SEQ ID NO: 320), og/eller det tredje peptid omfatter aminosyresekvensen FPEQPIPEQPQPYPQQ (SEQ ID NO: 321); (b) det første, andet og/eller tredje peptid omfatter en N- terminal acetylgruppe eller pyroglutamatgruppe og/eller en C-terminal amidgruppe, fortrinsvis en N-terminal pyroglutamatgruppe og en C-terminal amidgruppe; (c) det første, andet og/eller tredje peptid er konjugeret til en forbindelse, hvor forbindelsen fortrinsvis er et adjuvans eller et MHC (major histocompatibility)-molekyle eller et bindingsfragment deraf; (d) to eller tre af det første, andet og tredje peptid er på en enkelt polypeptidkæde; og/eller; (e) sammensætningen omfatter et eller flere yderligere peptides, der omfatter en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209 og 210.
3. Sammensætning ifølge et hvilket som helst af kravene 1 til 2, hvor hver af det første, andet og tredje peptid uafhængigt er mellem 7 og 50 aminosyrer langt, eller hvor hver af det første, andet og tredje peptid er 20 eller færre aminosyrer langt.
4. Sammensætning ifølge krav 1, der omfatter: i) et første peptid, der består af aminosyresekvensen LQPFPQPELPYPQPQ (SEQ ID NO: 13) og en N-terminal og/eller C-terminal modifikation, fortrinsvis hvor det første peptid består af aminosyresekvensen pyroELQPFPQPELPYPQPQ-amid (SEQ ID NO: 228); ii) et andet peptid, der består af aminosyresekvensen QPFPQPEQPFPWQP (SEQ ID NO: 14) og en N-terminal og/eller C-terminal modifikation, fortrinsvis hvor det andet peptid består af aminosyresekvensen pyroEQPFPQPEQPFPWQP-amid (SEQ ID NO: 229); og iii) et tredje peptid, der består af aminosyresekvensen PEQPIPEQPQPYPQQ (SEQ ID NO: 16) og en N-terminal og/eller C-terminal modifikation, fortrinsvis hvor det tredje peptid består af aminosyresekvensen pyroEPEQPIPEQPQPYPQQ-amid (SEQ ID NO: 230) .
5. Sammensætning, der omfatter et eller flere polynukleotider, der koder for i) et første peptid, der omfatter aminosyresekvensen PFPQPELPY (SEQ ID NO: 3) eller aminosyresekvensen PQPELPYPQ (SEQ ID NO: 4), ii) et andet peptid, der omfatter aminosyresekvensen PFPQPEQPF (SEQ ID NO: 10) eller aminosyresekvensen PQPEQPFPW (SEQ ID NO: 15), og iii) et tredje peptid, der omfatter aminosyresekvensen PIPEQPQPY (SEQ ID NO: 17) eller aminosyresekvensen EQPIPEQPQ (SEQ ID NO: 18) eller aminosyresekvensen QQPIPEQPQ (SEQ ID NO: 19).
6. Sammensætning ifølge krav 5, der yderligere omfatter et eller flere polynukleotider, der koder for et eller flere yderligere peptider, der omfatter en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209 og 210.
7. Vaccine, der omfatter sammensætningen ifølge et hvilket som helst af kravene 1 til 6 og et farmaceutisk acceptabelt bæremateriale.
8. Vaccine ifølge krav 7, der yderligere omfatter et adj uvans.
9. Kit, der omfatter sammensætningen ifølge et hvilket som helst af kravene 1 til 5 og et middel til påvisning af binding af et eller flere peptider til T-celler.
10. Isoleret antigenpræsenterende celle, der omfatter peptiderne, polynukleotidet eller polynukleotiderne ifølge et hvilket som helst af kravene 1 til 6.
11. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, vaccine ifølge et hvilket som helst af kravene 7 til 8, kit ifølge krav 9 og/eller antigenpræsenterende celle ifølge krav 10 til anvendelse til diagnosticering eller terapi.
12. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, vaccine ifølge et hvilket som helst af kravene 7 til 8 og/eller antigenpræsenterende celle ifølge krav 10 til anvendelse til: (a) modulering af en T-cellerespons på et glutenpeptid hos en person, der er overfølsom over for gluten; (b) inducering af immuntolerans over for et glutenpeptid hos en person, der er overfølsom over for gluten; (c) behandling af cøliaki hos en person, der er overfølsom over for gluten; eller (d) modificering af cytokinsekretion hos en person, der er overfølsom over for gluten.
13. Fremgangsmåde til diagnosticering af cøliaki hos en person, overvågning af progression af cøliaki eller bestemmelse af effekten af en sammensætning, en vaccine og/eller en antigenpræsenterende celle til anvendelse ifølge krav 12, hvilken fremgangsmåde omfatter etablering af kontakt mellem en prøve fra personen og sammensætningen ifølge et hvilket som helst af kravene 1 til 6 og/eller vaccinen ifølge et hvilket som helst af kravene 7 til 8 og bestemmelse in vitro af, om et eller flere af peptiderne binder T-celler i prøven, hvor binding af et eller flere peptider til T-celler indikerer, at personen har eller er disponeret for cøliaki.
14. Fremgangsmåde til fremstilling af vaccinen ifølge krav 7 eller 8, hvilken fremgangsmåde omfatter kombinering af det første, andet og tredje peptid med et farmaceutisk acceptabelt bæremateriale.
15. Fremgangsmåde til bestemmelse af, om en anden sammensætning eller en fødevare er i stand til at forårsage cøliaki, hvilken fremgangsmåde omfatter påvisning af tilstedeværelse af sammensætningen ifølge et hvilket som helst af kravene 1 til 5 i den anden sammensætning eller fødevaren.
16. Sammensætning, vaccine og/eller antigenpræsenterende celle ifølge krav 12 til anvendelse ifølge krav 12, hvor sekretion af interleukin-2 (IL—2), interferon-gamma (IFNy) og/eller tumornekrosefaktor-alfa (TNFa) reduceres, og/eller sekretion af interleukin-10 (IL-10) forøges.
DK15168279.6T 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki DK2977053T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11864308P 2008-11-30 2008-11-30
EP20090828453 EP2367561B1 (en) 2008-11-30 2009-11-30 Compositions and methods for treatment of celiac disease

Publications (1)

Publication Number Publication Date
DK2977053T3 true DK2977053T3 (da) 2017-10-09

Family

ID=42225141

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09828453.2T DK2367561T3 (da) 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki
DK15168279.6T DK2977053T3 (da) 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09828453.2T DK2367561T3 (da) 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki

Country Status (16)

Country Link
US (5) US8835603B2 (da)
EP (3) EP3269379A1 (da)
JP (2) JP5851243B2 (da)
CN (2) CN102438643B (da)
AU (1) AU2009321481B2 (da)
BR (1) BRPI0922122A2 (da)
CA (2) CA2744787C (da)
DK (2) DK2367561T3 (da)
ES (2) ES2549481T3 (da)
HK (1) HK1249446A1 (da)
HR (1) HRP20150873T1 (da)
HU (1) HUE027237T2 (da)
MX (1) MX346450B (da)
NZ (1) NZ593474A (da)
PT (1) PT2367561E (da)
WO (1) WO2010060155A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
EP1755639B1 (en) 2004-04-28 2017-08-16 BTG International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
US8835603B2 (en) 2008-11-30 2014-09-16 Immusant, Inc. Agents for the treatment of celiac disease
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
MX354089B (es) * 2011-01-20 2018-02-09 Cyrex Laboratories Llc Metodos y aparato para la deteccion de sensibilidad al gluten y su diferenciacion de la enfermedad celiaca.
ITRM20110487A1 (it) * 2011-09-19 2013-03-20 Consiglio Per La Ricerca E La Speri Mentazione In Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca.
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
JP6012767B2 (ja) 2012-02-07 2016-10-25 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 基板、ペプチドアレイ、および方法
DK2863942T3 (da) 2012-06-21 2019-07-15 Univ Northwestern Peptidkonjugerede partikler
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
RU2015142245A (ru) 2013-03-13 2017-04-18 Кур Фармасьютикалз Дивелопмент Компани Иммуномодифицирующие частицы для лечения воспаления
AU2014240046A1 (en) * 2013-03-14 2015-10-08 Robert P. Anderson Placebo-controlled gluten challenge method
US20160145636A1 (en) * 2013-05-08 2016-05-26 Jm Biologicals Compositions and methods for the production of gluten free food products
HUE047329T2 (hu) 2013-08-13 2020-04-28 Univ Northwestern Peptiddel konjugált részecskék
AU2014318889B2 (en) * 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
AU2013400677A1 (en) * 2013-09-20 2016-05-12 Immusant, Inc. Compositions and methods related to oat sensitivity
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
WO2015164747A1 (en) * 2014-04-24 2015-10-29 Immusant, Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
US10900964B2 (en) 2014-09-10 2021-01-26 Vibrant Holdings, Llc Peptide microarrays and novel biomarkers for celiac disease
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
HK1244821A1 (zh) * 2014-11-21 2018-08-17 Immusant Inc. 用於治疗和诊断1型糖尿病中使用的肽
KR101736744B1 (ko) 2014-12-03 2017-05-17 주식회사 한국유전자정보연구원 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180250359A1 (en) * 2015-08-30 2018-09-06 Diamyd Medical Ab Combination therapy using gliadin and gamma aminobutyric acid
CA3008892A1 (en) 2015-12-23 2017-06-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
WO2017143346A1 (en) 2016-02-18 2017-08-24 Cour Pharmaceuticals Development Company, Inc. Process for the preparation of tolerizing immune-modulating particles
EP3464322B1 (en) * 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
CA3029560A1 (en) 2016-06-28 2018-01-04 Immusant, Inc. Escalating dosage schedules for treating celiac disease
BR112019014418A2 (pt) * 2017-01-12 2020-04-14 Probi Ab composições probióticas e usos das mesmas
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
AU2018357840A1 (en) * 2017-10-30 2020-05-14 Immusant, Inc. Dosing regimens for celiac disease
JP6568193B2 (ja) 2017-12-19 2019-08-28 ホーユー株式会社 エピトープ
CN111867565A (zh) * 2018-02-08 2020-10-30 库尔制药发展公司股份有限公司 使用耐受颗粒治疗乳糜泻
JP2021528371A (ja) 2018-05-09 2021-10-21 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 免疫寛容に関する組成物および方法
CA3099046A1 (en) 2018-05-09 2019-11-14 Vibrant Holdings, Llc Methods of synthesizing a polynucleotide array using photoactivated agents________________________________________________________
EP3882261A4 (en) * 2018-10-31 2023-02-08 Ajinomoto Co., Inc. COMPOUND COMPRISING A SUBSTANCE HAVING AN AFFINITY FOR AN ANTIBODY, CLEAVAGE SITE AND CORRESPONDING REACTIVE GROUP OR SALT
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
US20230001010A1 (en) * 2019-07-19 2023-01-05 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
JP7374687B2 (ja) * 2019-09-26 2023-11-07 三和酒類株式会社 ペンタペプチド化合物
EP4061403A4 (en) * 2019-11-19 2023-12-27 Spark Therapeutics, Inc. SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
KR20230171998A (ko) 2021-04-16 2023-12-21 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 면역학적 관용의 유지를 추적하는 방법
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
WO2024168151A2 (en) * 2023-02-09 2024-08-15 The Board Of Trustees Of The Leland Stanford Junior University Capped peptides and methods for using the same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740371A (en) 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
DE3779909T2 (de) 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JPH10511541A (ja) 1994-08-26 1998-11-10 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｔ細胞応答を調節するための方法および組成物
NZ273815A (en) 1994-09-02 1999-05-28 Immulogic Pharma Corp Peptide compositions for treating protein allergies or autoimmune diseases containing at least two isolated and purified peptides
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1241476A1 (en) 2001-03-12 2002-09-18 Mabtech AB Diagnosis of metal allergy through cytokine release by T-cells in vitro
CA2440474A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
IL158342A0 (en) 2001-04-12 2004-05-12 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
EP1572127B2 (en) 2002-02-14 2014-10-29 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
WO2003096984A2 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
AU2003277989B2 (en) 2002-11-08 2010-04-22 QIAGEN Australia Holding Pty. Ltd. Diagnostic assay for measuring a cell mediated immune response
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
EP1755639B1 (en) * 2004-04-28 2017-08-16 BTG International Limited Epitopes related to coeliac disease
GB0409775D0 (en) 2004-04-30 2004-06-09 Mabtech Ab Assay
AU2005302425A1 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use
EP1937300A4 (en) 2005-08-17 2009-08-12 Multicell Immunotherapeutics I METHOD AND COMPOSITIONS FOR CREATING AND CONTROLLING THE EFFECTOR PROFILE OF T-CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUB-GROUPS OF ANTIGEN-PRESENTING CELLS
WO2007047303A2 (en) 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
CA2649296A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
ITFE20070003A1 (it) 2007-02-01 2007-05-03 Girolamo Calo' Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa
CN101711360A (zh) 2007-03-16 2010-05-19 赛乐思迪斯有限公司 细胞介导的免疫应答检验及其试剂盒
EP2659901B1 (en) 2008-04-21 2015-01-21 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
WO2009139887A2 (en) 2008-05-16 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue
CA2731854C (en) 2008-07-25 2020-06-30 Cellestis Limited Measurement of cell-mediated immune response reactivity to detect or monitor a disease or condition
US8835603B2 (en) 2008-11-30 2014-09-16 Immusant, Inc. Agents for the treatment of celiac disease
US20120107847A1 (en) 2009-07-02 2012-05-03 Dsm Ip Assets B.V. Testing efficacy for celiac disease
US9459253B2 (en) 2009-12-23 2016-10-04 Cellestis Limited Assay for measuring cell-mediated immunoresponsiveness
EP2577307B1 (en) 2010-05-28 2019-05-22 Cellestis Limited A diagnostic assay
US20110311536A1 (en) 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
TR201808740T4 (tr) 2011-06-29 2018-07-23 Cellestis Ltd Arttırılmış duyarlılığa sahip hücre aracılı bir immün yanıt tahlili.
WO2013016427A1 (en) 2011-07-25 2013-01-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
US20130058977A1 (en) 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Compositions and methods related to induced tolerogenic dendritic cells externally loaded with mhc class i-restricted epitopes
ES2402286B1 (es) 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
WO2013085851A2 (en) 2011-12-05 2013-06-13 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
AU2014240046A1 (en) 2013-03-14 2015-10-08 Robert P. Anderson Placebo-controlled gluten challenge method
AU2014318889B2 (en) 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
AU2013400677A1 (en) 2013-09-20 2016-05-12 Immusant, Inc. Compositions and methods related to oat sensitivity
WO2015164747A1 (en) 2014-04-24 2015-10-29 Immusant, Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines

Also Published As

Publication number Publication date
US20190048047A1 (en) 2019-02-14
JP6027215B2 (ja) 2016-11-16
CN102438643A (zh) 2012-05-02
ES2549481T3 (es) 2015-10-28
US9464120B2 (en) 2016-10-11
WO2010060155A1 (en) 2010-06-03
JP2012510431A (ja) 2012-05-10
CN105079781A (zh) 2015-11-25
EP3269379A1 (en) 2018-01-17
CA3042826A1 (en) 2010-06-03
JP2016128402A (ja) 2016-07-14
ES2642096T3 (es) 2017-11-15
AU2009321481B2 (en) 2014-08-21
EP2367561B1 (en) 2015-05-20
CA2744787C (en) 2019-06-11
MX346450B (es) 2017-03-17
EP2977053B1 (en) 2017-07-05
PT2367561E (pt) 2015-10-23
NZ593474A (en) 2013-04-26
BRPI0922122A2 (pt) 2017-08-01
HK1219898A1 (en) 2017-04-21
MX2011005632A (es) 2011-11-29
HUE027237T2 (en) 2016-10-28
EP2367561A1 (en) 2011-09-28
HK1249446A1 (en) 2018-11-02
US20110293644A1 (en) 2011-12-01
CN102438643B (zh) 2015-07-01
US20150050303A1 (en) 2015-02-19
US20210115096A1 (en) 2021-04-22
DK2367561T3 (da) 2015-08-24
CA2744787A1 (en) 2010-06-03
CN105079781B (zh) 2018-07-20
HK1162918A1 (en) 2012-09-07
HRP20150873T1 (hr) 2015-11-06
EP2977053A1 (en) 2016-01-27
JP5851243B2 (ja) 2016-02-03
US20170158743A1 (en) 2017-06-08
AU2009321481A1 (en) 2011-07-07
EP2367561A4 (en) 2012-06-06
US8835603B2 (en) 2014-09-16

Similar Documents

Publication Publication Date Title
DK2977053T3 (da) Sammensætninger og fremgangsmåder til behandling af cøliaki
US20200141924A1 (en) Peptides for use in treatment and diagnosis of type 1 diabetes
AU2018274876A1 (en) Compositions and methods for treatment of celiac disease
US20160238590A1 (en) Compositions and methods related to oat sensitivity
PL219272B1 (pl) Sekwencja DNA oraz sposób otrzymywania rekombinowanego alergenu pyłku traw Phl p4
HK1219898B (en) Compositions and methods for treatment of celiac disease
HK1162918B (en) Compositions and methods for treatment of celiac disease